Idera Pharmaceuticals, Inc. Announces Presentation of Preclinical Data on IMO-3100, a Lead TLR Antagonist Drug Candidate for Autoimmune Diseases, during American Association of Immunologists Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the presentation of data from a preclinical study of antagonist effects of IMO-3100 on gene expression profiles induced by ligands of specific Toll-like Receptors (TLRs). The presentation entitled “IMO-3100, an Antagonist of Toll-like Receptors 7 and 9, Modulates Gene Expression and Regulatory Networks Induced by Ligands” was given by Idera scientists during the Autoimmunity session at the 2009 Annual Meeting of The American Association of Immunologists being held in Seattle, WA May 8-12, 2009. IMO-3100 is the Company’s lead TLR7 and TLR9 antagonist drug candidate for potential application in autoimmune diseases.

Back to news